Journal Article

Isolation of a New Clathrin Heavy Chain Gene with Muscle-Specific Expression from the Region Commonly Deleted in Velo-cardio-facial Syndrome

Howard Sirotkin, Bernice Morrow, Ruchira DasGupta, Rosalie Goldberg, Sankhavaram R. Patanjali, Guangping Shi, Linda Cannizzaro, Robert Shprintzen, Sherman M. Weissman and Raju Kucherlapati

in Human Molecular Genetics

Volume 5, issue 5, pages 617-624
Published in print May 1996 | ISSN: 0964-6906
Published online May 1996 | e-ISSN: 1460-2083 | DOI: http://dx.doi.org/10.1093/hmg/5.5.617
Isolation of a New Clathrin Heavy Chain Gene with Muscle-Specific Expression from the Region Commonly Deleted in Velo-cardio-facial Syndrome

Show Summary Details

Preview

Velo-cardio-facial syndrome (VCFS) and DiGeorge syndrome (DGS) are developmental disorders characterized by a spectrum of phenotypes including velo-pharyngeal insufficiency, conotruncal heart defects and facial dysmorphology among others. Eighty to eighty-five percent of VCFS/DGS patients are hemizygous for a portion of chromosome 22. It is likely that the genes encoded by this region play a role in the etiology of the phenotypes associated with the disorders. Using a cDNA selection protocol, we isolated a novel clathrin heavy chain cDNA (CLTD) from the VCFS/DGS minimally deleted interval. The cDNA encodes a protein of 1638 amino acids. CLTD shares significant homology, but is not identical to the ubiquitously expressed clathrin heavy chain gene. The CLTD gene also shows a unique pattern of expression, having its maximal level of expression in skeletal muscle. Velopharyngeal insufficiency and muscle weakness are common features of VCFS patients. Based on the location and expression pattern of CLTD, we suggest hemizygosity at this locus may play a role in the etiology of one of the VCFS-associated phenotypes.

Journal Article.  6454 words.  Illustrated.

Subjects: Genetics and Genomics

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.